Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	31.19	52.89	76.33	109.11	112.58	85.21
Short-Term Investments	-	-	-	-	33.82	41.7
Cash & Short-Term Investments	31.19	52.89	76.33	109.11	146.4	126.91
Cash Growth	-50.90%	-30.71%	-30.04%	-25.47%	15.36%	54.68%
Accounts Receivable	-	49.39	49.15	-	-	-
Other Receivables	-	3.09	1.55	1.08	2.64	6.18
Receivables	-	52.48	50.7	1.08	2.64	6.18
Prepaid Expenses	-	1.91	4.18	3.38	8.83	6.06
Total Current Assets	31.19	107.28	131.21	113.57	157.87	139.15
Property, Plant & Equipment	-	3.11	4.16	5.49	7.56	8.78
Long-Term Accounts Receivable	-	-	46.59	-	-	-
Other Long-Term Assets	30.93	0.15	0.44	5.74	5.64	5.52
Total Assets	62.12	110.54	182.39	124.8	171.07	153.45
Accounts Payable	-	7.31	1.38	0.62	1.1	1.16
Accrued Expenses	-	17.27	6.56	8.53	14.35	12.24
Current Portion of Leases	-	1.75	1.72	1.69	1.36	0.95
Current Income Taxes Payable	-	0.17	0.39	-	-	-
Current Unearned Revenue	-	22.12	27.11	10.37	1.86	-
Other Current Liabilities	-	0.46	-	0.45	-	-
Total Current Liabilities	-	49.07	37.15	21.65	18.67	14.34
Long-Term Debt	-	-	-	-	48.41	-
Long-Term Leases	-	2.55	3.83	4.96	5.97	6.89
Long-Term Unearned Revenue	-	12.8	34.43	22.17	8.79	-
Other Long-Term Liabilities	29.29	-	0.09	0.1	0.94	0.18
Total Liabilities	29.29	64.42	75.5	48.87	82.78	21.41
Common Stock	32.83	0.06	0.05	0.05	0.03	0.03
Additional Paid-In Capital	-	505.71	497.91	489.76	455.72	409.72
Retained Earnings	-	-459.64	-391.07	-413.88	-367.46	-277.71
Comprehensive Income & Other	-	-	-	-	-0	-0.01
Total Common Equity	32.83	46.12	106.89	75.93	88.29	132.04
Shareholders' Equity	32.83	46.12	106.89	75.93	88.29	132.04
Total Liabilities & Equity	62.12	110.54	182.39	124.8	171.07	153.45
Total Debt	-	4.3	5.54	6.65	55.75	7.84
Net Cash (Debt)	31.19	48.59	70.79	102.46	90.65	119.07
Net Cash Growth	-46.76%	-31.36%	-30.91%	13.02%	-23.86%	55.64%
Net Cash Per Share	0.57	0.90	1.34	2.73	2.93	5.32
Filing Date Shares Outstanding	56.03	55.9	53.87	52.57	32.76	29.5
Total Common Shares Outstanding	56.03	54.59	53	52.46	32.39	29.26
Working Capital	31.19	58.2	94.06	91.92	139.2	124.8
Book Value Per Share	0.59	0.84	2.02	1.45	2.73	4.51
Tangible Book Value	32.83	46.12	106.89	75.93	88.29	132.04
Tangible Book Value Per Share	0.59	0.84	2.02	1.45	2.73	4.51
Machinery	-	1.55	1.55	1.55	1.76	1.76
Construction In Progress	-	-	-	-	-	0.04
Leasehold Improvements	-	1.64	1.64	1.64	1.64	1.64

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q